⚠
Is this information incorrect? This profile was AI-generated from publicly available sources and may contain errors. If you are a representative of Cytokinetics, Incorporated and believe any information on this page is inaccurate, we will promptly correct or remove it.REPORT AN ERROR
Cytokinetics, Incorporated
↗South San Francisco, USA
Cytokinetics is a late-stage biopharmaceutical company focused on the discovery, development, and commercialization of muscle-directed medicines. The company specializes in small molecule therapeutics that target the sarcomere to treat diseases characterized by impaired muscle function, such as heart failure and hypertrophic cardiomyopathy (HCM).
With over 25 years of research, the company is transitioning toward a commercial-stage entity with a focus on its Vision 2030 strategy. Its pipeline includes several investigational candidates, with aficamten being a primary focus for regulatory approval and commercial launch in the United States and international markets.
CLASSIFICATION
Company Type:Biotech
Therapeutic Areas:
Industry:Biotechnology
Sub-Industry:Cardiovascular and Neuromuscular Therapeutics
SIZE & FINANCIALS
Employees:501-1000
Revenue:$10M-$50M
Founded:1998
Ownership:public
Status:operating
FUNDING
Investors:Brown Advisory Inc., TD Asset Management Inc.
STOCK
Exchange:NASDAQ
Ticker:CYTK
PIPELINE
Stage:Commercial
Lead Drug Stage:Phase 3 / Regulatory Review
Modalities:Small molecule
Active Trials:100
Trial Phases:-
FDA Approvals:0
EMA Approvals:0
CORPORATE STRUCTURE
Key Partnerships:Various research institutions for clinical trials
COMPETITION
Position:Leader
Competitors:Bristol Myers Squibb, MyoKardia (acquired), Edgewise Therapeutics
LEADERSHIP
Key Executives:
Robert I. Blum - President and CEO
Stuart Kupfer - SVP, Chief Medical Officer
Board Members:Muna Bhanji
LINKS
Website:cytokinetics.com
LinkedIn:LinkedIn Profile
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with Cytokinetics, Incorporated. The information on this page was compiled using AI from publicly available sources and may be incomplete, outdated, or contain errors. We are committed to correcting inaccuracies promptly upon notice. For official information, please visit the company's website directly.